Serum FGF21 levels are elevated in association with lipodystrophy, insulin resistance and biomarkers of liver injury in HIV-1-infected patients

AIDS

Volumn 24, Issue 17, 2010, Pages 2629-2637

  Domingo, Pere ^a   Gallego Escuredo, José M ^b   Domingo, Joan C ^b   Gutiérrez, Maria Del Mar ^a   Mateo, Maria G ^a   Fernández, Irene ^a   Vidal, Francesc ^c   Giralt, Marta ^b   Villarroya, Francesc ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

antiretroviral drugs; FGF21; insulin resistance; lipodystrophy; metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD LEVEL; BODY FAT DISTRIBUTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE MARKER; DYSLIPIDEMIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPODYSTROPHY; LIPOPROTEIN BLOOD LEVEL; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADULT; ANTHROPOMETRY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; FEMALE; FIBROBLAST GROWTH FACTORS; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INSULIN RESISTANCE; LIVER; MALE; RISK FACTORS;

EID: 78349310229     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283400088     Document Type: Article

References (34)

1. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnorm-alities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
2. Villarroya F, Domingo P, Giralt M. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int J Obes (Lond) 2007; 31:1763-1776.
3. Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006; 194:642-650.
4. Flint OP, Noor MA, Hruz PW, Hylemon PB, Yarasheski K, Kotler DP, et al. The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clin-ical implications. Toxicol Pathol 2009; 37:65-77.
5. Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009; 23: 1109-1118.
6. Sutinen J. The effects ofthiazolidinediones on metabolic com-plications and lipodystrophy in HIV-infected patients. PPAR Res 2009; 2009:373524.
7. Mart́inez E, Domingo P, Ribera E, Milinkovic A, Arroyo JA, Conget I, et al. 2003 Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors. Antivir Ther 2003; 8:403-410.
8. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115:1627-1635.
9. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008; 149:6018-6027.
10. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, in-creases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58:250-259.
11. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPAR-alpha-mediated induction of fibroblast growth factor 21. Cell Metab 2007; 5:415-425.
12. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS. Maratos-Flier E 2007 Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007; 5:426-437.
13. Hondares E, Rosell M, Gonzalez FJ, Giralt M, Iglesias R, Villarroya F. Hepatic FGF21 expression is induced at birth via PPARalpha in response to milk intake and contributes to thermogenic activation of neonatal brown fat. Cell Metab 2010; 11:206-212.
14. Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M, et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58:1532-1538.
15. Gälman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafström I. The circulating metabolic regulator FGF21 is in-duced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8:169-174.
16. Christodoulides C, Dyson P, Sprecher D, Tsintzas K, Karpe F. Circulating fibroblast growth factor 21 is induced by peroxi-some proliferator-activated receptor agonists but not ketosis in man. J Clin Endocrinol Metab 2009; 94:3594-3601.
17. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expres-sionof a novel endocrine regulatorfibroblastgrowthfactor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71:369-375.
18. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in hu-mans. Diabetes 2008; 57:1246-1253.
19. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating Fibroblast Growth Fac-tor-21 (FGF-21) is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32:1542-1546.
20. Centers for Disease Control. Revised classification system for HIV infection and expanded surveillance for case definition for AIDS among adolescents and adults. Morb Mortal Wkly Rep 1993; 41:1-13.
21. Lemieux S, Prud'homme D, Bouchard C, Tremblay A, Despres JP. 1996 A single threshold ofwaist girth identifies normal-weight and overweight subjects with excess visceral adipose tissue. Am J Clin Nutr 1996; 64:685-693.
22. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39:395-400.
23. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circula-tion 2005; 112:2735-2752.
24. Sugiuchi H, Uji Y, Okabe H, Irie T, Uekama K, Kayahara N, et al. Direct measurement of high-density lipoprotein choles-terol in serum with polyethylene glycol-modified enzymes and sulfated alpha-cyclodextrin. Clin Chem 1995; 41:717-723.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985 Homeostasis model assessment: insulin re-sistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 8:412-419.
26. Giralt M, Domingo P, Guallar JP, de la Concepcion ML, Alegre M, Domingo JC,et al. HIV-1 infection alters geneexpression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006; 11:11729-11740.
27. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-in-fected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
28. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma- glutamyltransferase but not insulin sensitivity in Chi-nese subjects. J Clin Endocrinol Metab 2009; 94:2151-2156.
29. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139:456-463.
30. Moreno-Torres A, Domingo P, Pujol J, Blanco-Vaca F, Arroyo JA, Sambeat MA. Liver triglyceride content in HIV-1-infected patients on combination antiretroviral therapy studied with 1 H-MR spectroscopy. Antivir Ther 2007; 12:195-203.
31. Mohammed SS, Aghdassi E, Salit IE, Avand G, Sherman M, Guindi M, et al. HIV-positive patients with nonalcoholic fatty liver disease have a lower body mass index and are more physically active than HIV-negative patients.JAcquir Immune Defic Syndr 2007; 45:432-438.
32. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, et al. Increased fat accumula-tion in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16:2183 2193.
33. Hotta Y, Nakamura H, Konishi M, Murata Y, Takagi H, Matsumura S, et al. 2009 Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for keto-genesisand triglycerideclearance in liver. Endocrinology2009; 150:4625-4633.
34. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Rydén M. FGF21 attenuates lipolysis in human adipocytes-a possible link to improved insulin sensitivity. FEBS Lett 2008; 582:1725-1730.